ProKidney (PROK) Financials

ProKidney logo
$1.04 -0.02 (-1.89%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.06 +0.02 (+1.92%)
As of 11/20/2026 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for ProKidney

Annual Income Statements for ProKidney

This table shows ProKidney's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-27 -55 -108 -35 -61 -69
Consolidated Net Income / (Loss)
-27 -55 -148 -135 -163 -152
Net Income / (Loss) Continuing Operations
-27 -55 -148 -135 -163 -152
Total Pre-Tax Income
-27 -55 -147 -129 -164 -151
Total Operating Income
-27 -55 -153 -152 -184 -165
Total Gross Profit
0.00 0.00 0.00 0.00 0.08 0.89
Total Revenue
0.00 0.00 0.00 0.00 0.08 0.89
Operating Revenue
- - 0.00 0.00 0.08 0.89
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
27 55 153 152 184 166
Selling, General & Admin Expense
5.98 8.86 71 45 56 52
Research & Development Expense
21 46 82 107 128 114
Total Other Income / (Expense), net
0.04 0.00 5.77 22 20 14
Interest Expense
0.00 0.00 0.22 0.01 0.01 0.00
Interest & Investment Income
0.04 0.00 5.98 22 20 14
Income Tax Expense
-0.23 0.04 0.90 6.00 -0.60 0.41
Net Income / (Loss) Attributable to Noncontrolling Interest
0.00 0.00 -40 -100 -102 -83
Basic Earnings per Share
$0.00 $0.00 ($0.23) ($0.57) ($0.62) ($0.52)
Weighted Average Basic Shares Outstanding
0.00 0.00 61.54M 61.71M 97.92M 133.94M
Diluted Earnings per Share
$0.00 $0.00 ($0.23) ($0.57) ($0.62) ($0.52)
Weighted Average Diluted Shares Outstanding
0.00 0.00 61.54M 61.71M 97.92M 133.94M
Weighted Average Basic & Diluted Shares Outstanding
- - 234.92M 229.34M 292.70M 301.92M

Quarterly Income Statements for ProKidney

This table shows ProKidney's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-9.49 -13 -18 30 -17 -17 -16 -19 -20 -28 -36
Consolidated Net Income / (Loss)
-35 -38 -41 -48 -38 -37 -36 -41 -43 -46 -52
Net Income / (Loss) Continuing Operations
-35 -38 -41 -48 -38 -37 -36 -41 -43 -46 -52
Total Pre-Tax Income
-35 -39 -43 -47 -37 -36 -35 -42 -43 -46 -52
Total Operating Income
-40 -43 -49 -52 -41 -40 -39 -45 -45 -48 -54
Total Gross Profit
0.00 0.00 0.00 0.08 0.23 0.22 0.22 0.23 0.23 0.15 0.17
Total Revenue
0.00 0.00 0.00 0.08 0.23 0.22 0.22 0.23 0.23 0.15 0.17
Operating Revenue
0.00 0.00 0.00 - 0.23 0.22 0.22 0.23 0.23 0.15 0.17
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
40 43 49 52 42 40 39 46 45 49 54
Selling, General & Admin Expense
13 14 18 12 14 14 12 11 11 12 13
Research & Development Expense
27 29 31 40 27 26 27 34 34 36 41
Total Other Income / (Expense), net
4.84 4.53 5.58 4.79 4.03 3.59 3.26 2.93 2.31 1.94 1.53
Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00
Interest & Investment Income
4.84 4.54 5.58 4.79 4.03 3.59 3.26 2.94 2.33 1.94 1.53
Income Tax Expense
0.10 -0.06 -2.34 1.70 0.59 0.85 0.56 -1.59 0.00 0.00 -0.44
Net Income / (Loss) Attributable to Noncontrolling Interest
-26 -26 -23 -79 -21 -20 -19 -22 -23 -18 -16
Basic Earnings per Share
($0.16) ($0.16) ($0.14) ($0.16) ($0.13) ($0.13) ($0.12) ($0.14) ($0.14) ($0.15) ($0.17)
Weighted Average Basic Shares Outstanding
60.95M 75.91M 126.17M 97.92M 126.98M 130.73M 134.99M 133.94M 141.93M 186.56M 207.76M
Diluted Earnings per Share
($0.16) ($0.16) ($0.14) ($0.16) ($0.13) ($0.13) ($0.12) ($0.14) ($0.14) ($0.15) ($0.17)
Weighted Average Diluted Shares Outstanding
60.95M 75.91M 126.17M 97.92M 126.98M 130.73M 134.99M 133.94M 141.93M 186.56M 207.76M
Weighted Average Basic & Diluted Shares Outstanding
231.70M 289.68M 291.66M 292.70M 292.70M 294.28M 300.83M 301.92M 302.06M 302.32M 302.38M

Annual Cash Flow Statements for ProKidney

This table details how cash moves in and out of ProKidney's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-11 16 470 -430 38 9.42
Net Cash From Operating Activities
-25 -50 -77 -90 -126 -120
Net Cash From Continuing Operating Activities
-25 -50 -77 -90 -126 -120
Net Income / (Loss) Continuing Operations
-27 -55 -148 -135 -163 -152
Consolidated Net Income / (Loss)
-27 -55 -148 -135 -163 -152
Depreciation Expense
0.96 1.98 3.04 3.85 5.43 6.58
Non-Cash Adjustments To Reconcile Net Income
0.73 0.70 74 25 28 24
Changes in Operating Assets and Liabilities, net
-0.13 2.16 -6.46 17 3.96 1.28
Net Cash From Investing Activities
-5.46 -5.19 -1.74 -330 20 104
Net Cash From Continuing Investing Activities
-5.46 -5.19 -1.74 -330 20 104
Purchase of Property, Plant & Equipment
-5.46 -5.19 -1.85 -34 -30 -15
Purchase of Investments
- 0.00 0.00 -472 -324 -217
Divestitures
- - - 0.00 0.00 18
Sale and/or Maturity of Investments
- 0.00 0.00 176 374 318
Net Cash From Financing Activities
20 71 549 -9.55 144 26
Net Cash From Continuing Financing Activities
20 71 549 -9.55 144 26
Repurchase of Common Equity
- 0.00 0.00 -9.50 0.00 0.00
Issuance of Common Equity
0.00 0.00 0.00 0.00 144 24
Other Financing Activities, net
20 71 549 -0.05 0.09 1.32

Quarterly Cash Flow Statements for ProKidney

This table details how cash moves in and out of ProKidney's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
24 130 -106 -8.97 -1.32 -13 10 13 -6.64 -27 6.49
Net Cash From Operating Activities
-35 -38 -29 -24 -30 -31 -27 -33 -42 -40 -39
Net Cash From Continuing Operating Activities
-35 -38 -29 -24 -30 -31 -27 -33 -42 -40 -39
Net Income / (Loss) Continuing Operations
-35 -38 -41 -48 -38 -37 -36 -41 -43 -46 -52
Consolidated Net Income / (Loss)
-35 -38 -41 -48 -38 -37 -36 -41 -43 -46 -52
Depreciation Expense
1.10 1.27 1.49 1.57 1.60 1.47 1.67 1.84 1.66 1.68 1.67
Non-Cash Adjustments To Reconcile Net Income
5.39 6.42 11 5.34 5.65 5.98 6.27 5.75 4.53 5.34 5.79
Changes in Operating Assets and Liabilities, net
-5.81 -7.52 -0.27 18 1.11 -1.89 1.30 0.76 -5.25 -0.95 5.68
Net Cash From Investing Activities
58 29 -82 15 28 19 29 28 35 13 45
Net Cash From Continuing Investing Activities
58 29 -82 15 28 19 29 28 35 13 45
Purchase of Property, Plant & Equipment
-0.96 -0.64 -2.40 -26 -1.14 -3.11 -5.20 -5.75 -3.79 -3.83 -1.23
Sale and/or Maturity of Investments
115 57 115 87 85 64 113 56 83 49 46
Net Cash From Financing Activities
-0.01 140 4.46 0.12 -0.01 -0.01 7.96 18 0.22 0.54 0.05
Net Cash From Continuing Financing Activities
-0.01 140 4.46 0.12 -0.01 -0.01 7.96 18 0.22 0.54 0.05
Other Financing Activities, net
-0.01 -0.01 -0.01 0.13 -0.01 -0.01 0.86 0.49 0.21 0.54 0.05

Annual Balance Sheets for ProKidney

This table presents ProKidney's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
40 518 421 441 336
Total Current Assets
27 505 374 396 281
Cash & Equivalents
21 490 61 99 109
Short-Term Investments
- 0.00 302 259 161
Prepaid Expenses
6.69 13 9.81 16 6.73
Other Current Assets
0.03 1.38 1.38 22 3.93
Plant, Property, & Equipment, net
11 11 42 42 51
Total Noncurrent Assets
1.67 2.57 4.26 2.97 3.66
Other Noncurrent Operating Assets
1.24 2.36 4.26 2.97 3.66
Total Liabilities & Shareholders' Equity
40 518 421 441 336
Total Liabilities
13 13 29 39 35
Total Current Liabilities
12 11 25 36 31
Accounts Payable
2.83 3.04 5.10 3.63 0.94
Accrued Expenses
9.21 7.34 18 31 29
Other Current Liabilities
0.27 0.49 0.80 0.77 1.07
Total Noncurrent Liabilities
1.07 2.18 4.18 3.22 4.04
Noncurrent Deferred Revenue
0.00 0.28 0.57 0.75 1.07
Other Noncurrent Operating Liabilities
1.07 1.91 3.61 2.47 2.97
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 1,602 1,495 1,397 1,312
Total Equity & Noncontrolling Interests
27 -1,097 -1,103 -995 -1,011
Total Preferred & Common Equity
27 -1,097 -1,103 -995 -1,011
Total Common Equity
27 -1,097 -1,103 -995 -1,011
Common Stock
188 7.50 36 206 259
Retained Earnings
-162 -1,104 -1,140 -1,201 -1,270
Accumulated Other Comprehensive Income / (Loss)
- 0.00 0.13 0.13 0.06

Quarterly Balance Sheets for ProKidney

This table presents ProKidney's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2023 6/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
495 484 388 499 475 406 372 352 293 249 210
Total Current Assets
480 466 340 450 430 360 324 300 235 190 151
Cash & Equivalents
272 244 84 215 108 98 85 95 102 75 81
Short-Term Investments
192 203 245 217 299 231 210 176 123 107 61
Prepaid Expenses
11 12 9.26 16 17 9.98 8.02 7.87 7.13 6.48 7.71
Other Current Assets
5.68 8.69 1.90 2.75 6.13 21 22 20 2.83 1.73 1.87
Plant, Property, & Equipment, net
12 15 42 43 39 43 44 48 54 56 56
Total Noncurrent Assets
3.20 2.99 5.67 6.33 6.05 3.07 4.17 3.87 3.44 3.21 3.01
Other Noncurrent Operating Assets
3.04 2.88 5.67 6.33 6.05 3.07 4.17 3.87 3.44 3.21 3.01
Total Liabilities & Shareholders' Equity
495 484 388 499 475 406 372 352 293 249 210
Total Liabilities
14 27 25 27 31 36 33 33 30 26 33
Total Current Liabilities
11 24 19 21 25 33 28 29 26 23 30
Accounts Payable
3.80 2.83 3.38 2.93 2.85 3.12 2.44 1.94 2.59 1.61 2.52
Accrued Expenses
6.85 21 13 15 21 28 25 26 22 20 26
Other Current Liabilities
0.62 0.65 1.09 1.03 1.07 0.86 0.90 0.99 1.11 1.13 1.11
Total Noncurrent Liabilities
2.89 2.78 5.43 6.21 6.14 3.28 4.42 4.21 3.75 3.47 3.27
Capital Lease Obligations
- - 4.86 - - 2.51 - 3.25 2.68 - 2.14
Noncurrent Deferred Revenue
0.43 0.49 0.57 0.57 0.77 0.76 0.90 0.96 1.07 1.07 1.12
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
2,082 1,779 1,459 1,445 1,423 1,369 1,342 1,326 1,287 1,106 1,084
Total Equity & Noncontrolling Interests
-1,602 -1,322 -1,096 -972 -980 -999 -1,003 -1,008 -1,024 -884 -907
Total Preferred & Common Equity
-1,602 -1,322 -1,096 -972 -980 -999 -1,003 -1,008 -1,024 -884 -907
Total Common Equity
-1,602 -1,322 -1,096 -972 -980 -999 -1,003 -1,008 -1,024 -884 -907
Common Stock
22 31 53 189 200 219 232 243 266 435 447
Retained Earnings
-1,623 -1,353 -1,149 -1,162 -1,180 -1,218 -1,234 -1,251 -1,290 -1,318 -1,354
Accumulated Other Comprehensive Income / (Loss)
-0.02 -0.13 -0.04 -0.01 0.32 0.08 0.03 0.07 -0.05 -0.03 -0.04

Annual Metrics And Ratios for ProKidney

This table displays calculated financial ratios and metrics derived from ProKidney's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
- - - - - 300,834,379.00
DEI Adjusted Shares Outstanding
- - - - - 300,834,379.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - -0.23
Growth Metrics
- - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 1,075.00%
EBITDA Growth
0.00% -103.86% -182.29% 1.54% -20.71% 11.12%
EBIT Growth
0.00% -103.93% -177.64% 0.97% -21.22% 10.16%
NOPAT Growth
0.00% -103.93% -177.64% 0.97% -21.22% 10.16%
Net Income Growth
0.00% -106.16% -168.62% 8.57% -20.59% 7.18%
EPS Growth
0.00% 0.00% 0.00% -147.83% -8.77% 16.13%
Operating Cash Flow Growth
0.00% -99.75% -53.26% -16.84% -40.28% 4.93%
Free Cash Flow Firm Growth
0.00% 0.00% -156.88% -3.75% -19.85% 28.28%
Invested Capital Growth
0.00% 0.00% 130.96% 93.27% 52.70% -29.00%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 20.03%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% 4.14% -17.80% 3.92%
EBIT Q/Q Growth
0.00% 0.00% 0.00% 3.82% -17.50% 3.62%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% 3.82% -17.50% 3.62%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 2.06% -19.59% 4.79%
EPS Q/Q Growth
0.00% 0.00% 0.00% 1.72% -12.73% 3.70%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -3.73% -11.96% 0.95% -7.46%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 1.74% 22.63%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 0.00% 18.25% -38.27%
Profitability Metrics
- - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 100.00% 100.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% -234,531.58% -17,741.55%
Operating Margin
0.00% 0.00% 0.00% 0.00% -241,678.95% -18,477.83%
EBIT Margin
0.00% 0.00% 0.00% 0.00% -241,678.95% -18,477.83%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% -214,914.47% -16,977.83%
Tax Burden Percent
99.14% 100.07% 100.61% 104.63% 99.64% 100.27%
Interest Burden Percent
99.84% 100.00% 96.23% 85.43% 89.25% 91.63%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% -358.49% -311.67%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% -348.85% -300.17%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 317.29% 268.50%
Return on Equity (ROE)
0.00% -204.87% -55.70% -30.22% -41.20% -43.17%
Cash Return on Invested Capital (CROIC)
0.00% -1,413.30% -1,096.96% -556.10% -400.20% -277.75%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% -42.63% -42.49%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% -37.91% -39.04%
Return on Common Equity (ROCE)
0.00% -204.87% 112.04% 74.19% 109.01% 123.29%
Return on Equity Simple (ROE_SIMPLE)
0.00% -204.87% 13.51% 12.28% 16.42% 0.00%
Net Operating Profit after Tax (NOPAT)
-19 -39 -107 -106 -129 -116
NOPAT Margin
0.00% 0.00% 0.00% 0.00% -169,175.26% -12,934.48%
Net Nonoperating Expense Percent (NNEP)
0.00% -161.19% -16.06% -6.89% -9.64% -11.49%
Return On Investment Capital (ROIC_SIMPLE)
- - 9.77% 9.61% 12.92% 11.42%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 73,794.74% 5,798.10%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 167,984.21% 12,779.73%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 241,778.95% 18,577.83%
Earnings before Interest and Taxes (EBIT)
-27 -55 -153 -152 -184 -165
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-26 -53 -150 -148 -178 -158
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 6,485.64 754.61
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 184.38 54.62 35.33 55.75
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 20,147.47 1,921.44
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.00 -0.76 -0.96 -0.95 -0.91 -0.89
Leverage Ratio
0.00 1.50 1.05 1.05 1.09 1.11
Compound Leverage Factor
0.00 1.50 1.01 0.89 0.97 1.01
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 317.18% 381.96% 347.72% 436.18%
Common Equity to Total Capital
0.00% 100.00% -217.18% -281.96% -247.72% -336.18%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 0.00 70.56 4.61 3.29 5.60
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 301.13% 345.46% 364.62% 385.60%
Liquidity Ratios
- - - - - -
Current Ratio
0.00 2.21 46.42 14.94 10.93 9.13
Quick Ratio
0.00 1.67 45.09 14.50 9.89 8.78
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -45 -115 -120 -144 -103
Operating Cash Flow to CapEx
-461.53% -968.97% -4,176.00% -263.38% -428.18% -790.45%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 -536.90 -9,980.37 -15,948.02 -25,733.98
Operating Cash Flow to Interest Expense
0.00 0.00 -358.55 -7,505.75 -14,039.00 -30,029.25
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -367.14 -10,355.50 -17,317.78 -33,828.25
Efficiency Ratios
- - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.02
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - -
Invested Capital
0.00 6.36 15 28 43 31
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.02
Increase / (Decrease) in Invested Capital
0.00 6.36 8.33 14 15 -13
Enterprise Value (EV)
0.00 0.00 2,708 1,551 1,531 1,716
Market Capitalization
200 0.00 1,597 419 493 674
Book Value per Share
$0.00 $0.84 ($4.71) ($4.69) ($3.41) ($3.36)
Tangible Book Value per Share
$0.00 $0.83 ($4.71) ($4.69) ($3.41) ($3.36)
Total Capital
0.00 27 505 391 402 301
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 -21 -490 -363 -358 -270
Capital Expenditures (CapEx)
5.46 5.19 1.85 34 30 15
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -5.60 3.59 -14 1.38 -20
Debt-free Net Working Capital (DFNWC)
0.00 15 494 349 360 250
Net Working Capital (NWC)
0.00 15 494 349 360 250
Net Nonoperating Expense (NNE)
7.83 17 41 29 35 36
Net Nonoperating Obligations (NNO)
0.00 -21 -490 -363 -358 -270
Total Depreciation and Amortization (D&A)
0.96 1.98 3.04 3.85 5.43 6.58
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 1,809.21% -2,248.60%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 473,246.05% 27,988.47%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 473,246.05% 27,988.47%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($0.23) ($0.57) ($0.62) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 61.54M 61.71M 97.92M 133.94M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($0.23) ($0.57) ($0.62) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 61.54M 61.71M 97.92M 133.94M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 234.92M 229.34M 292.70M 301.92M
Normalized Net Operating Profit after Tax (NOPAT)
-19 -39 -107 -106 -129 -116
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% -169,175.26% -12,934.48%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% -215,701.32% -16,931.47%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
0.00 0.00 -711.66 -12,626.83 -20,408.44 -41,251.75
NOPAT to Interest Expense
0.00 0.00 -498.16 -8,838.78 -14,285.91 -28,876.23
EBIT Less CapEx to Interest Expense
0.00 0.00 -720.25 -15,476.58 -23,687.22 -45,050.75
NOPAT Less CapEx to Interest Expense
0.00 0.00 -506.75 -11,688.53 -17,564.69 -32,675.23
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -7.01% 0.00% 0.00%

Quarterly Metrics And Ratios for ProKidney

This table displays calculated financial ratios and metrics derived from ProKidney's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - 300,834,379.00 301,916,085.00 302,059,626.00 302,322,655.00
DEI Adjusted Shares Outstanding
- - - - - - - 300,834,379.00 301,916,085.00 302,059,626.00 302,322,655.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - -0.06 -0.07 -0.09 -0.12
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 196.05% -1.74% -32.13% -19.82%
EBITDA Growth
2.67% -7.28% -4.11% -116.78% -2.09% 8.48% 22.37% 12.93% -8.76% -22.10% -41.28%
EBIT Growth
1.96% -8.13% -5.05% -113.02% -3.27% 7.77% 21.31% 12.02% -8.57% -21.82% -39.49%
NOPAT Growth
1.96% -8.13% -5.05% -113.02% -3.27% 7.77% 21.31% 12.02% -8.57% -21.82% -39.49%
Net Income Growth
4.27% -10.46% 2.23% -123.18% -7.41% 3.90% 12.69% 15.74% -12.30% -25.62% -44.50%
EPS Growth
0.00% -14.29% 22.22% -77.78% 18.75% 18.75% 14.29% 12.50% -7.69% -15.38% -41.67%
Operating Cash Flow Growth
-33.29% -156.72% -22.98% 4.78% 14.59% 17.96% 9.05% -34.51% -40.86% -28.51% -45.33%
Free Cash Flow Firm Growth
-125.92% -130.60% -325.51% -66.61% 31.39% 47.33% 43.36% 62.41% 16.94% 4.03% 37.71%
Invested Capital Growth
124.87% 277.54% 0.00% 52.70% 13.10% 9.53% 36.02% -29.00% -7.17% -7.72% -25.28%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 202.63% -3.91% -1.81% 3.69% 0.44% -33.63% 16.00%
EBITDA Q/Q Growth
-68.98% -7.22% -13.64% -5.29% 20.42% 3.88% 3.60% -18.09% 0.59% -7.90% -11.54%
EBIT Q/Q Growth
-65.53% -7.44% -13.74% -5.31% 19.75% 4.06% 2.95% -17.73% 0.97% -7.66% -11.13%
NOPAT Q/Q Growth
-65.53% -7.44% -13.74% -5.31% 19.75% 4.06% 2.95% -17.73% 0.97% -7.66% -11.13%
Net Income Q/Q Growth
-62.65% -8.87% -6.73% -18.10% 21.72% 2.60% 3.04% -13.97% -4.33% -8.95% -11.54%
EPS Q/Q Growth
-77.78% 0.00% 12.50% -14.29% 18.75% 0.00% 7.69% -16.67% 0.00% -7.14% -13.33%
Operating Cash Flow Q/Q Growth
-36.49% -10.53% 23.64% 17.34% -22.43% -6.16% 15.34% -22.25% -28.21% 3.14% 4.27%
Free Cash Flow Firm Q/Q Growth
-62.02% -21.16% -17.92% 28.02% 33.28% 6.99% -26.80% 52.24% -47.45% -7.47% 17.70%
Invested Capital Q/Q Growth
37.03% 4.99% -10.23% 18.25% 1.49% 1.67% 11.48% -38.27% 32.68% 1.08% -9.74%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
0.00% 0.00% 0.00% -65,785.53% -17,299.13% -17,304.98% -16,988.94% -19,348.44% -19,148.23% -31,130.00% -29,933.91%
Operating Margin
0.00% 0.00% 0.00% -67,856.58% -17,994.78% -17,967.87% -17,759.91% -20,164.89% -19,881.86% -32,248.67% -30,895.40%
EBIT Margin
0.00% 0.00% 0.00% -67,856.58% -17,994.78% -17,967.87% -17,759.91% -20,164.89% -19,881.86% -32,248.67% -30,895.40%
Profit (Net Income) Margin
0.00% 0.00% 0.00% -63,793.42% -16,500.87% -16,726.24% -16,517.51% -18,156.44% -18,858.85% -30,957.33% -29,766.09%
Tax Burden Percent
100.28% 99.85% 94.60% 103.64% 101.58% 102.35% 101.59% 96.27% 100.00% 100.00% 99.17%
Interest Burden Percent
87.92% 89.47% 88.61% 90.71% 90.27% 90.95% 91.55% 93.53% 94.85% 96.00% 97.16%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% -100.65% -93.01% -154.94% -213.82% -340.12% -291.71% -429.44% -384.80%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% -97.22% -90.24% -152.42% -211.20% -337.23% -287.64% -424.16% -377.87%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 88.42% 80.04% 136.35% 187.21% 301.64% 249.10% 359.28% 311.41%
Return on Equity (ROE)
-31.72% -29.59% -30.80% -12.23% -12.97% -18.59% -26.61% -38.48% -42.61% -70.15% -73.40%
Cash Return on Invested Capital (CROIC)
-452.39% -533.54% -797.01% -400.20% -324.75% -306.31% -307.57% -277.75% -270.74% -280.47% -280.33%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% -11.97% -13.87% -21.74% -31.98% -46.37% -50.58% -84.94% -85.23%
Return on Assets (ROA)
0.00% 0.00% 0.00% -11.25% -12.72% -20.23% -29.74% -41.75% -47.98% -81.54% -82.11%
Return on Common Equity (ROCE)
101.39% 73.07% 68.04% 32.36% 37.05% 45.22% 69.43% 109.90% 136.13% 235.31% 283.75%
Return on Equity Simple (ROE_SIMPLE)
12.21% 14.14% 13.94% 0.00% 16.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-28 -30 -34 -36 -29 -28 -27 -32 -31 -34 -38
NOPAT Margin
0.00% 0.00% 0.00% -47,499.61% -12,596.35% -12,577.51% -12,431.94% -14,115.42% -13,917.30% -22,574.07% -21,626.78%
Net Nonoperating Expense Percent (NNEP)
-1.85% -1.90% -3.33% -3.43% -2.76% -2.52% -2.63% -2.89% -4.07% -5.28% -6.94%
Return On Investment Capital (ROIC_SIMPLE)
2.57% - - 3.63% 2.91% 2.77% 2.68% 3.14% 3.08% 3.83% 4.16%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 15,613.16% 6,241.30% 6,356.56% 5,500.00% 5,084.00% 5,007.52% 8,285.33% 7,521.26%
R&D to Revenue
0.00% 0.00% 0.00% 52,343.42% 11,853.48% 11,711.31% 12,359.91% 15,180.89% 14,974.34% 24,063.33% 23,474.14%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 67,956.58% 18,094.78% 18,067.87% 17,859.91% 20,264.89% 19,981.86% 32,348.67% 30,995.40%
Earnings before Interest and Taxes (EBIT)
-40 -43 -49 -52 -41 -40 -39 -45 -45 -48 -54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-39 -42 -47 -50 -40 -38 -37 -44 -43 -47 -52
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 6,485.64 838.11 328.86 957.21 754.61 607.91 753.30 647.56
Price to Earnings (P/E)
19.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
5.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
38.85 38.77 42.90 35.33 29.53 27.29 35.50 55.75 39.31 37.34 38.81
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 20,147.47 4,245.12 2,316.00 2,379.09 1,921.44 1,805.45 1,883.87 1,865.76
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01
Long-Term Debt to Equity
0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01
Financial Leverage
-0.93 -0.94 -0.92 -0.91 -0.89 -0.89 -0.89 -0.89 -0.87 -0.85 -0.82
Leverage Ratio
1.05 1.06 1.07 1.09 1.08 1.07 1.08 1.11 1.10 1.10 1.13
Compound Leverage Factor
0.92 0.95 0.95 0.99 0.98 0.98 0.99 1.03 1.05 1.06 1.10
Debt to Total Capital
1.32% 0.00% 0.00% 0.00% 0.67% 0.00% 1.01% 0.00% 1.01% 0.00% 1.20%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
1.32% 0.00% 0.00% 0.00% 0.67% 0.00% 1.01% 0.00% 1.01% 0.00% 1.20%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
396.61% 305.85% 320.92% 347.72% 367.40% 395.33% 412.45% 436.18% 484.19% 496.49% 605.09%
Common Equity to Total Capital
-297.93% -205.85% -220.92% -247.72% -268.08% -295.33% -313.46% -336.18% -385.20% -396.49% -506.28%
Debt to EBITDA
-0.03 0.00 0.00 0.00 -0.01 0.00 -0.02 0.00 -0.02 0.00 -0.01
Net Debt to EBITDA
2.21 0.00 0.00 0.00 1.82 0.00 1.63 0.00 1.37 0.00 0.75
Long-Term Debt to EBITDA
-0.03 0.00 0.00 0.00 -0.01 0.00 -0.02 0.00 -0.02 0.00 -0.01
Debt to NOPAT
-0.05 0.00 0.00 0.00 -0.02 0.00 -0.03 0.00 -0.02 0.00 -0.02
Net Debt to NOPAT
3.07 0.00 0.00 0.00 2.52 0.00 2.24 0.00 1.88 0.00 1.04
Long-Term Debt to NOPAT
-0.05 0.00 0.00 0.00 -0.02 0.00 -0.03 0.00 -0.02 0.00 -0.02
Altman Z-Score
5.63 10.25 7.86 4.28 0.70 -0.86 8.43 6.78 5.11 6.88 -0.12
Noncontrolling Interest Sharing Ratio
419.61% 346.92% 320.92% 364.62% 385.75% 343.26% 360.92% 385.60% 419.44% 435.42% 486.60%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
17.62 21.87 17.09 10.93 10.96 11.48 10.32 9.13 9.06 8.36 5.04
Quick Ratio
17.05 20.96 16.16 9.89 10.01 10.43 9.35 8.78 8.67 7.99 4.72
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-50 -60 -71 -51 -34 -32 -40 -19 -28 -30 -25
Operating Cash Flow to CapEx
-3,608.96% -6,020.91% -1,216.35% -94.75% -2,607.22% -1,009.51% -511.76% -565.25% -1,101.29% -1,053.33% -3,132.17%
Free Cash Flow to Firm to Interest Expense
-24,826.10 -20,052.73 -35,468.55 -25,529.35 0.00 -31,686.30 -20,089.65 -19,190.70 -1,886.47 -30,410.10 -25,027.60
Operating Cash Flow to Interest Expense
-17,323.00 -12,764.33 -14,620.50 -12,085.50 0.00 -31,416.00 -13,298.00 -32,513.00 -2,778.93 -40,374.00 -38,651.00
Operating Cash Flow Less CapEx to Interest Expense
-17,803.00 -12,976.33 -15,822.50 -24,840.00 0.00 -34,528.00 -15,896.50 -38,265.00 -3,031.27 -44,207.00 -39,885.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.02 0.02 0.02 0.02
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
39 41 37 43 44 45 50 31 41 41 37
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.02 0.02 0.02 0.02
Increase / (Decrease) in Invested Capital
22 30 37 15 5.10 3.89 13 -13 -3.16 -3.45 -13
Enterprise Value (EV)
1,511 1,583 1,573 1,531 1,299 1,221 1,770 1,716 1,605 1,541 1,446
Market Capitalization
376 570 556 493 256 173 712 674 540 616 502
Book Value per Share
($4.78) ($4.20) ($3.38) ($3.41) ($3.41) ($3.43) ($3.43) ($3.36) ($3.39) ($2.93) ($3.00)
Tangible Book Value per Share
($4.78) ($4.20) ($3.38) ($3.41) ($3.41) ($3.43) ($3.43) ($3.36) ($3.39) ($2.93) ($3.00)
Total Capital
368 472 443 402 372 339 322 301 266 223 179
Total Debt
4.86 0.00 0.00 0.00 2.51 0.00 3.25 0.00 2.68 0.00 2.14
Total Long-Term Debt
4.86 0.00 0.00 0.00 2.51 0.00 3.25 0.00 2.68 0.00 2.14
Net Debt
-324 -432 -407 -358 -326 -295 -268 -270 -222 -182 -140
Capital Expenditures (CapEx)
0.96 0.64 2.40 26 1.14 3.11 5.20 5.75 3.79 3.83 1.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-8.14 -1.86 -1.77 1.38 -1.64 1.45 -0.80 -20 -16 -15 -20
Debt-free Net Working Capital (DFNWC)
321 430 405 360 327 296 271 250 209 167 121
Net Working Capital (NWC)
321 430 405 360 327 296 271 250 209 167 121
Net Nonoperating Expense (NNE)
7.28 8.33 6.77 12 8.98 9.17 8.87 9.09 11 13 14
Net Nonoperating Obligations (NNO)
-324 -432 -407 -358 -326 -295 -268 -270 -222 -182 -140
Total Depreciation and Amortization (D&A)
1.10 1.27 1.49 1.57 1.60 1.47 1.67 1.84 1.66 1.68 1.67
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 1,809.21% -537.25% 275.14% -107.39% -2,248.60% -1,796.74% -1,773.35% -2,638.84%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 473,246.05% 106,815.03% 56,200.76% 36,414.78% 27,988.47% 23,506.30% 20,422.74% 15,666.19%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 473,246.05% 106,815.03% 56,200.76% 36,414.78% 27,988.47% 23,506.30% 20,422.74% 15,666.19%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.16) ($0.16) ($0.14) ($0.16) ($0.13) ($0.13) ($0.12) ($0.14) ($0.14) ($0.15) ($0.17)
Adjusted Weighted Average Basic Shares Outstanding
60.95M 75.91M 126.17M 97.92M 128.98M 130.73M 134.99M 133.94M 141.93M 186.56M 207.76M
Adjusted Diluted Earnings per Share
($0.16) ($0.16) ($0.14) ($0.16) ($0.13) ($0.13) ($0.12) ($0.14) ($0.14) ($0.15) ($0.17)
Adjusted Weighted Average Diluted Shares Outstanding
60.95M 75.91M 126.17M 97.92M 128.98M 130.73M 134.99M 133.94M 141.93M 186.56M 207.76M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
231.70M 289.68M 291.66M 292.70M 292.70M 294.28M 300.83M 301.92M 302.06M 302.32M 302.38M
Normalized Net Operating Profit after Tax (NOPAT)
-28 -30 -34 -36 -29 -28 -27 -32 -31 -34 -38
Normalized NOPAT Margin
0.00% 0.00% 0.00% -47,499.61% -12,596.35% -12,577.51% -12,431.94% -14,115.42% -13,917.30% -22,574.07% -21,626.78%
Pre Tax Income Margin
0.00% 0.00% 0.00% -61,553.95% -16,243.91% -16,342.53% -16,259.45% -18,860.89% -18,858.85% -30,957.33% -30,016.67%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-20,038.00 -14,352.00 -24,486.50 -25,785.50 0.00 -39,709.00 -19,269.50 -45,371.00 -2,995.53 -48,373.00 -53,758.00
NOPAT to Interest Expense
-14,026.60 -10,046.40 -17,140.55 -18,049.85 0.00 -27,796.30 -13,488.65 -31,759.70 -2,096.87 -33,861.10 -37,630.60
EBIT Less CapEx to Interest Expense
-20,518.00 -14,564.00 -25,688.50 -38,540.00 0.00 -42,821.00 -21,868.00 -51,123.00 -3,247.87 -52,206.00 -54,992.00
NOPAT Less CapEx to Interest Expense
-14,506.60 -10,258.40 -18,342.55 -30,804.35 0.00 -30,908.30 -16,087.15 -37,511.70 -2,349.21 -37,694.10 -38,864.60
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ProKidney’s latest quarter shows a company still focused primarily on research and development rather than commercial operations. In Q2 2026, revenue was just $150,000, while research and development expenses reached $36.1 million. The company remains unprofitable and continues to consume cash, although it maintains a sizable portfolio of cash and short-term investments.

  • Strong near-term liquidity: ProKidney held $74.9 million in cash and $106.7 million in short-term investments at June 30, 2026, or approximately $181.6 million in highly liquid assets.
  • Low traditional debt burden: Total liabilities were $26.2 million, consisting largely of accounts payable and accrued expenses rather than significant interest-bearing debt.
  • Healthy current-asset coverage: Current assets of $189.8 million were more than eight times current liabilities of $22.7 million, providing substantial short-term balance-sheet flexibility.
  • Investment income continues to offset some operating costs: Interest and investment income was $1.9 million in Q2 2026, helping reduce the quarterly pretax loss.
  • Research investment remains substantial: R&D spending was $36.1 million in Q2 2026 and $33.8 million in Q1, indicating continued investment in ProKidney’s clinical and development programs.
  • Revenue remains minimal but recurring: Quarterly revenue has been reported near $150,000 to $226,000 since early 2025, compared with no revenue in much of 2023 and 2024. However, the current level is not meaningful relative to operating expenses.
  • Investment portfolio is being actively managed: ProKidney sold or received maturities of $48.7 million in investments during Q2 while purchasing $32.0 million, producing $12.8 million of net investing cash flow. This supports liquidity but is not an operating source of cash.
  • Operating losses remain severe: Q2 2026 operating expenses totaled $48.5 million against only $150,000 of revenue, resulting in an operating loss of $48.4 million. The company has reported operating losses in every period shown.
  • Cash burn remains high: Operating cash outflow was $40.4 million in Q2 2026 after $41.7 million in Q1. The company’s cash and short-term investment balance has fallen from approximately $512 million in Q2 2024 to $181.6 million in Q2 2026.
  • Common shareholders face dilution and negative equity: Weighted average basic shares increased to 186.6 million in Q2 2026 from 141.9 million in Q1. Common equity was negative $883.5 million, while redeemable noncontrolling interest was $1.1 billion, making the capital structure complex and unfavorable for common shareholders.

Q2 2026 net loss was $46.4 million, compared with losses of $42.6 million in Q1 2026 and $40.9 million in Q4 2025. The loss attributable to common shareholders increased to $28.4 million, or $0.15 per share, from $20.0 million, or $0.14 per share, in Q1. This deterioration occurred despite lower SG&A spending than in early 2025, because R&D costs remain elevated and revenue has not scaled.

The balance sheet provides some time to advance the company’s pipeline, but the trend is weakening. Total assets declined from $406.1 million in Q1 2025 to $249.0 million in Q2 2026, primarily because cash and investments have been used to fund operations. At the recent quarterly operating cash-burn rate of roughly $40 million, the liquid asset balance represents less than five quarters of coverage before considering changes in spending, investment income, financing, or asset sales.

For investors, the central issue is whether ProKidney can convert its research spending into meaningful clinical progress and eventually commercial revenue before its liquidity is substantially depleted. Until revenue grows materially, the stock remains dependent on clinical execution, continued access to capital, and management’s ability to control cash burn.

11/22/26 06:40 AM ETAI Generated. May Contain Errors.

ProKidney Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ProKidney's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ProKidney's net income appears to be on a downward trend, with a most recent value of -$151.61 million in 2025, falling from -$26.75 million in 2020. The previous period was -$163.34 million in 2024. See ProKidney's forecast for analyst expectations on what's next for the company.

ProKidney's total operating income in 2025 was -$165.01 million, based on the following breakdown:
  • Total Gross Profit: $893 thousand
  • Total Operating Expenses: $165.90 million

Over the last 5 years, ProKidney's total revenue changed from $0.00 in 2020 to $893 thousand in 2025, a change of 89,300,000.0%.

In the past 14 quarters, ProKidney's cash and equivalents has ranged from $74.87 million in Q2 2026 to $271.64 million in Q1 2023, and is currently $81.36 million as of their latest financial filing in Q3 2026.

ProKidney had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2020.

Over the last 5 years, ProKidney's book value per share changed from 0.00 in 2020 to -3.36 in 2025.



Financial statements for NASDAQ:PROK last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners